189 related articles for article (PubMed ID: 23614999)
1. Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068.
Ray N; Hwang C; Healy MD; Whitcomb J; Lataillade M; Wind-Rotolo M; Krystal M; Hanna GJ
J Acquir Immune Defic Syndr; 2013 Sep; 64(1):7-15. PubMed ID: 23614999
[TBL] [Abstract][Full Text] [Related]
2. Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068.
Zhou N; Nowicka-Sans B; McAuliffe B; Ray N; Eggers B; Fang H; Fan L; Healy M; Langley DR; Hwang C; Lataillade M; Hanna GJ; Krystal M
J Antimicrob Chemother; 2014 Mar; 69(3):573-81. PubMed ID: 24128669
[TBL] [Abstract][Full Text] [Related]
3. In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043.
Zhou N; Nowicka-Sans B; Zhang S; Fan L; Fang J; Fang H; Gong YF; Eggers B; Langley DR; Wang T; Kadow J; Grasela D; Hanna GJ; Alexander L; Colonno R; Krystal M; Lin PF
Antimicrob Agents Chemother; 2011 Feb; 55(2):729-37. PubMed ID: 21078948
[TBL] [Abstract][Full Text] [Related]
4. Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
Schapiro JM; Boucher CA; Kuritzkes DR; van de Vijver DA; Llibre JM; Lewis M; Simpson P; Delogne C; McFadyen L; Chapman D; Perros M; Valdez H; van der Ryst E; Westby M
Antivir Ther; 2011; 16(3):395-404. PubMed ID: 21555822
[TBL] [Abstract][Full Text] [Related]
5. Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529.
Landry I; Zhu L; Abu Tarif M; Hruska M; Sadler BM; Pitsiu M; Joshi S; Hanna GJ; Lataillade M; Boulton DW; Bertz RJ
Antimicrob Agents Chemother; 2016 May; 60(5):2782-9. PubMed ID: 26902761
[TBL] [Abstract][Full Text] [Related]
6. Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects.
Hanna GJ; Lalezari J; Hellinger JA; Wohl DA; Nettles R; Persson A; Krystal M; Lin P; Colonno R; Grasela DM
Antimicrob Agents Chemother; 2011 Feb; 55(2):722-8. PubMed ID: 21078951
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.
Lataillade M; Lalezari JP; Kozal M; Aberg JA; Pialoux G; Cahn P; Thompson M; Molina JM; Moreno S; Grinsztejn B; Diaz RS; Castagna A; Kumar PN; Latiff GH; De Jesus E; Wang M; Chabria S; Gartland M; Pierce A; Ackerman P; Llamoso C
Lancet HIV; 2020 Nov; 7(11):e740-e751. PubMed ID: 33128903
[TBL] [Abstract][Full Text] [Related]
8. Frequency of amino acid changes associated with resistance to attachment inhibitor BMS-626529 in R5- and X4-tropic HIV-1 subtype B.
Soulié C; Lambert-Niclot S; Fofana DB; Fourati S; Ait-Arkoub Z; Sayon S; Simon A; Katlama C; Calvez V; Marcelin AG
J Antimicrob Chemother; 2013 Jun; 68(6):1243-5. PubMed ID: 23396856
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients.
Charpentier C; Larrouy L; Visseaux B; Landman R; Levittas M; Storto A; Damond F; Yazdanpanah Y; Yeni P; Brun-Vézinet F; Descamps D
J Antimicrob Chemother; 2012 Jun; 67(6):1459-61. PubMed ID: 22382470
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects.
Nettles RE; Schürmann D; Zhu L; Stonier M; Huang SP; Chang I; Chien C; Krystal M; Wind-Rotolo M; Ray N; Hanna GJ; Bertz R; Grasela D
J Infect Dis; 2012 Oct; 206(7):1002-11. PubMed ID: 22896665
[TBL] [Abstract][Full Text] [Related]
11. Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.
Li Z; Zhou N; Sun Y; Ray N; Lataillade M; Hanna GJ; Krystal M
Antimicrob Agents Chemother; 2013 Sep; 57(9):4172-80. PubMed ID: 23774428
[TBL] [Abstract][Full Text] [Related]
12. Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.
Lataillade M; Zhou N; Joshi SR; Lee S; Stock DA; Hanna GJ; Krystal M;
J Acquir Immune Defic Syndr; 2018 Mar; 77(3):299-307. PubMed ID: 29206721
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.
Zhu L; Hruska M; Hwang C; Shah V; Furlong M; Hanna GJ; Bertz R; Landry IS
Antimicrob Agents Chemother; 2015 Jul; 59(7):3816-22. PubMed ID: 25870057
[TBL] [Abstract][Full Text] [Related]
14. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.
Kozal M; Aberg J; Pialoux G; Cahn P; Thompson M; Molina JM; Grinsztejn B; Diaz R; Castagna A; Kumar P; Latiff G; DeJesus E; Gummel M; Gartland M; Pierce A; Ackerman P; Llamoso C; Lataillade M;
N Engl J Med; 2020 Mar; 382(13):1232-1243. PubMed ID: 32212519
[TBL] [Abstract][Full Text] [Related]
15. Randomized placebo-controlled study of the safety, tolerability, antiviral activity, and pharmacokinetics of 10-day monotherapy with BMS-986001, a novel HIV NRTI, in treatment-experienced HIV-1-infected subjects.
Cotte L; Dellamonica P; Raffi F; Yazdanpanah Y; Molina JM; Boué F; Urata Y; Chan HP; Zhu L; Chang I; Bertz R; Hanna GJ; Grasela DM; Hwang C
J Acquir Immune Defic Syndr; 2013 Jul; 63(3):346-54. PubMed ID: 23771104
[TBL] [Abstract][Full Text] [Related]
16. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.
Emu B; Fessel J; Schrader S; Kumar P; Richmond G; Win S; Weinheimer S; Marsolais C; Lewis S
N Engl J Med; 2018 Aug; 379(7):645-654. PubMed ID: 30110589
[TBL] [Abstract][Full Text] [Related]
17. Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.
Price DA; Scullard G; Oxenius A; Braganza R; Beddows SA; Kazmi S; Clarke JR; Johnson GE; Weber JN; Phillips RE
J Virol; 2003 May; 77(10):6041-9. PubMed ID: 12719595
[TBL] [Abstract][Full Text] [Related]
18. Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes.
Fofana DB; Charpentier C; Maïga AI; Lambert-Niclot S; Sayon S; Désiré N; Simon A; Yazdanpanah Y; Katlama C; Descamps D; Calvez V; Marcelin AG; Soulié C
J Antimicrob Chemother; 2015 Jan; 70(1):130-5. PubMed ID: 25270328
[TBL] [Abstract][Full Text] [Related]
19. T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity.
Pulido I; Machmach K; Romero-Sánchez MC; Genebat M; Mendez-Lagares G; Ruiz-Mateos E; Leal M
J Infect; 2012 Apr; 64(4):417-23. PubMed ID: 22227467
[TBL] [Abstract][Full Text] [Related]
20. Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir.
Alessandri-Gradt E; Charpentier C; Leoz M; Mourez T; Descamps D; Plantier JC
J Antimicrob Chemother; 2018 Oct; 73(10):2716-2720. PubMed ID: 30032194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]